多西他赛联合奥沙利铂、卡培他滨一线治疗晚期胃癌临床观察

Clinical effect of Docetaxel combined with Oxaliplatin and Capecitabine on advanced gastric cancer

目的:评价多西他赛(TXT)联合奥沙利铂(OXA)、卡培他滨(Xeloda)治疗晚期胃癌的近期疗效及不良反应。方法:19例晚期胃癌患者接受多西他赛75mg/m2,d1,奥沙利铂85mg/m2,d2,卡培他滨每天1000mg/m2,bid,d1-14,21d为1个周期,化疗2个周期后评价疗效。结果:19例患者均可评价疗效,其中CR 1例(5.3%),PR 10例(52.6%),SD 5例(26.3%),PD 3例(15.8%),总有效率57.9%,中位TTP为5.8个月,中位OS为10.5个月;常见不良反应为骨髓抑制、胃肠道反应、外周神经毒性、脱发且多以Ⅰ-Ⅱ度为主。结论:多西他赛联合奥沙利铂、卡培他滨方案治疗晚期胃癌近期疗效好,不良反应可耐受。

Objective： To investigate the short term effect and adverse reactions in patients with advanced gastric cancer treated with the regimen of Docetaxel in combination with Oxaliplatin and Capecitabine. Methods： Nineteen patients were treated with the regimen as follows： Docetaxel 75 mg / m^2,intravenous,day 1; Oxaliplatin 85mg/m^2,intravenous,day 2; Capecitabine 1000 mg / m^2,twice a day,PO,for 14 days,21 days as a cycle. Evaluation was performed at the end of 2 cyeles. Results： All of these 19 patients were evaluable for response. One（ 5. 3%） complete response（ CR）,10（ 52. 6%） partial response（ PR）,5（ 26. 3%） stable disease（ SD）,3（ 15. 8%） disease progression（ PD）,with a total response rate（ RR） of 57. 9%. The median progression- free survival was 5. 8 months and the median overall survival time was 10. 5 months. The most common adverse effects were myelosuppression,gastrointestinal toxicities,neurotoxicity and alopecia which were primarilyⅠ- Ⅱ degree. Conclusion： Docetaxel combined with Oxaliplatin and Capecitabine is effective for advanced gastric cancer,with tolerable side effects.